drugset / Trial / NCT03403023

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

NCT03403023

Unknown 40 enrolled Meir Medical Center
NaSingle-groupOpen-labelDiagnostic

Summary

Dry Eye Syndrome (DES) is a disease affects the production and stability of the tear film, leading to vision disturbances and a major decrease in quality of life. The most recommended treatment for moderate-severe DES today which failed conservative therapy with lubricating eye drops is topical Cyclosporine 0.05% (Restasis®). The Tear Film Imager (TFI) is a novel imaging modality designed for visualization of the individual tear film layers up to a resolution of 0.1 micrometers, a property not enabled by any other imaging modality for this indication to date. In this study we wish to assess the effects of topical Cyclosporine 0.05% on the tear film using the TFI. In our previous study we found this modality yields high resolution images of the tear film, yielding significant differences between healthy and diseased (DES) eyes. We believe the TFI will improve quality of assessment and follow-up of DES patients, allowing more effective diagnosis and treatment of this disease in the future.

Timeline

Start
2018-01-30
Primary completion
2018-05-30
Completion
2018-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.05 % Topical

Indications